Last reviewed · How we verify
D660, placebo of D064, placebo of D702 — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
D660, placebo of D064, placebo of D702 (D660, placebo of D064, placebo of D702) — Chong Kun Dang Pharmaceutical. D660 is a placebo control formulation with no active pharmacological mechanism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| D660, placebo of D064, placebo of D702 TARGET | D660, placebo of D064, placebo of D702 | Chong Kun Dang Pharmaceutical | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- D660, placebo of D064, placebo of D702 CI watch — RSS
- D660, placebo of D064, placebo of D702 CI watch — Atom
- D660, placebo of D064, placebo of D702 CI watch — JSON
- D660, placebo of D064, placebo of D702 alone — RSS
Cite this brief
Drug Landscape (2026). D660, placebo of D064, placebo of D702 — Competitive Intelligence Brief. https://druglandscape.com/ci/d660-placebo-of-d064-placebo-of-d702. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab